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1. Introduction 
Periodontitis is one of the most common oral diseases and is characterised by gingival 
inflammation and alveolar bone resorption (Savage et al. 2009). Periodontitis is a 
multifactorial irreversible and cumulative condition, initiated and propagated by bacteria 
and host factors (Kinane 2001). More than 500 different bacterial species are able to colonise 
the oral biofilm and up to 150 different species of bacteria are possible in any individual’s 
subgingival plaque. There are two forms of periodontitis; chronic and aggressive 
periodontitis which differ from each other not only in clinical findings but also age of onset 
and rate of progression. Chronic periodontitis progresses more slowly compared to the 
aggressive forms of periodontitis and responds much better to periodontal treatment. 
According to a report by the World Health Organisation, severe chronic periodontitis 
leading to tooth loss was found in 5% to 15% of most populations worldwide (Armitage 
2004). Hence, it can be considered among the prevalent and important global health 
problems in terms of quality of life. 
The multifactorial nature of periodontitis is based on the complex interactions between 
microorganisms in the microbial dental plaque, namely dental biofilm, host response 
mechanisms and environmental factors. Smoking is well known to be the leading 
environmental factor that is closely related not only with the risk but also the prognosis of 
periodontitis. Indeed, the harmful effects of smoking on numerous organs have been well-
documented for years now. Cigarette smoking is recognised as the major preventable cause 
of death in the United States (Centres for Disease Control 2002 (CDC 2002)). Smoking is the 
second strongest modifiable risk factor for periodontal disease after the first one which is the 
microbial dental plaque. Smokers are more likely to harbour a higher prevalence of potential 
periodontal pathogens, and smoking impairs various aspects of innate and acquired 
immune responses. Numerous molecules in the oral fluids namely; gingival crevicular fluid 
(GCF) and saliva, as well as molecules in blood circulation; serum or plasma have been 
investigated so far in an attempt to provide a sensitive and specific marker for periodontal 
tissue destruction (Buduneli & Kinane 2011). The aim of the present literature review is to 
provide an overview of the evidence for smoking as a risk factor for chronic periodontitis 
and to discuss the possible mechanisms of action and finally the negative effects of smoking 
on the outcomes of periodontal treatment in patients with chronic periodontitis. 
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Smokers are accepted to be more susceptible to advanced and aggressive forms of 
periodontitis than non-smokers (Haber et al. 1993, Calsina et al. 2002) and former smokers 
are at decreased disease risk than current smokers (Bostrom et al. 2001). Tobacco smoking 
modifies the periodontal response to microbial challenge (Barbour et al. 1997, Palmer et al. 
2005). Although, smoker and non-smoker patients exhibit more or less the same periodontal 
pathogens (Preber et al. 1992, Buduneli et al. 2005a) smokers also tend to respond less 
favourably to periodontal treatment (Ah et al. 1994, Renvert et al. 1998). Smoking was 
suggested to influence host cytokine levels (Boström et al. 1999, Buduneli et al. 2005b, 
Buduneli et al. 2006). Furthermore, smoking was reported to reduce salivary osteoprotegerin 
concentrations in untreated and also treated chronic periodontitis patients (Buduneli et al. 
2008). Chronic periodontitis has been associated with various systemic diseases and/or 
conditions such as cardiovascular diseases and preterm low birth weight. Over the last 
decade there have been a number of reviews that have considered the biological 
mechanisms underlying  susceptibility to periodontitis in smokers (Barbour et al. 1997, 
Johnson & Hill 2004, Kinane & Chestnutt 2000, Mullally 2004, Palmer et al. 2005, Scott et al. 
2001). Despite that a clear dose-response relationship between chronic periodontitis and 
smoking was reported (Martinez-Canut et al. 1995) the mechanisms by which smoking 
contributes to the pathogenesis of periodontitis are not yet clearly understood. 
The fundamental mechanisms that lead to the development of chronic periodontitis are 
closely related to the dynamics of the host immune and inflammatory responses to 
periodontal pathogens present in the dental biofilm (Gemmell & Seymour 2004). The 
immune and inflammatory responses are critical to understanding the pathogenesis of 
periodontal diseases and they are orchestrated by a number of host-related factors, either 
intrinsic or induced (Taubman et al. 2005). Under normal circumstances, there is a balance 
between microbial virulence factors and host response. Tissue homeostasis is maintained as 
long as this balance is preserved. In periodontitis, this balance between the microbial 
virulence factors and host response is impaired in favour of microbial challenge. Smoking as 
an environmental factor has been suggested to interact with host cells and affect 
inflammatory responses to this microbial challenge (Palmer et al. 2005). It is also likely that 
the toxic components of tobacco smoke, mainly nicotine, may directly or indirectly 
deteriorate periodontal tissues. Cigarette smoking represents a risk factor for progression of 
periodontitis, the effect of which may be dose related. Heavy smokers should be considered 
as high-risk individuals for progression of periodontitis. The clinical implications for this are 
that smokers should be identified during patient examination and efforts should be made to 
modify this behavioural risk factor. Furthermore, smoking or molecules related to smoking 
such as blood cotinine induced by smoking should be considered as important risk markers 
of periodontal disease that are relevant to the assessment of prognosis (Calsina et al. 2002, 
Tang et al. 2009). 
Smokers are almost four times more likely to have severe periodontitis than non-smokers 
(Haber et al. 1993). Nicotine and lipopolysaccharide (LPS) effects on the expression of 
macrophage colony-stimulating factor (M-CSF), osteoprotegerin (OPG), and prostaglandin E2 
(PGE2) have been evaluated by Tanaka et al. (2006) in osteoblasts and osteoclast-like cells. OPG 
expression was increased in the initial stages of culture with nicotine and LPS but decreased in 
the later stages of culture. Apatzidou et al. (2005) stated that smokers with periodontal disease 
have a suppressed inflammatory response, a significantly less favourable clinical outcome and 
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seem to have an altered host antibody response to antigenic challenge than non-smokers 
although; the subgingival microflora of smokers appears similar to that of non-smokers. 
Lappin et al. (2007) reported decreased serum OPG levels and greater soluble receptor 
activator of nuclear- factor kappa B ligand (sRANKL) sRANKL/OPG ratios in smoker patients 
in the maintenance program than the non-smoker counterparts. Negative correlation between 
pack-years and total OPG amount in peri-implant crevicular fluid was detected in clinically 
healthy implants (Arıkan et al. 2008). Our recent finding of higher sRANKL, lower OPG 
concentrations in saliva of untreated/treated smokers than non-smokers (Buduneli et al. 2008) 
confirmed these findings. Furthermore, our saliva data (Buduneli et al. 2008) indicated that 
treated non-smokers had lower sRANKL levels than untreated non-smokers possibly 
indicating a more active inflammatory process in untreated patients. Although the exact GCF 
concentrations of RANKL and OPG varied from study to study, overall RANKL/OPG ratio 
showed a trend to increase in periodontitis compared to healthy controls (Mogi et al. 2004, Lu 
et al. 2006, Bostancı et al. 2007, Crotti et al. 2003). This may either be explained by an increase 
in RANKL or a decrease in OPG levels or both.  
Significantly lower plasma OPG concentrations were detected in smoker chronic 
periodontitis patients than the smoker healthy controls without any significant differences 
between the smoker and non-smoker study groups (Özçaka et al. 2010). That finding 
suggests that smoking alone may not be effective on plasma levels of RANKL/OPG system 
in periodontal disease but when it is coupled with periodontal inflammation the disturbing 
effect on bone homeostasis may become detectable. Moreover, the significant positive 
correlations found in the smoker groups between plasma OPG concentrations and probing 
depth may indicate a tendency towards increased bone metabolism which aims to 
compensate the increased susceptibility to alveolar bone resorption (Özçaka et al. 2010). 
Neither the clinical periodontal measurements nor the laboratory data obtained in plasma 
samples showed significant differences between the smoker and non-smoker chronic 
periodontitis patients (Özçaka et al. 2010). Indeed, the similarity in clinical periodontal 
findings between the smoker and non-smoker chronic periodontitis patient groups may 
explain the lack of significant differences in plasma levels of RANKL and OPG. Darby et al. 
(2005) suggested that the inferior improvement in probing depth following scaling and root 
planing in smoker chronic periodontitis patients may reflect the systemic effects of smoking 
on the host response, the healing process, and the poorer clearance of the microorganisms. 
The plasma data reported by Özçaka et al. (2010) are in line with the recent study by Tang et 
al. (2009) reporting similar sRANKL and OPG levels in GCF samples of never smokers, 
former smokers and current smokers. In that study the only significant difference could be 
found in GCF OPG levels of the high pack-years group and never smokers. 
It has been shown that not only the number of leukocytes is increased but also leukocytes 
particularly polymorphonuclear neutrophils (PMNs) are significantly activated in smokers, 
suggesting a systemic inflammatory state. Nicotine has been shown to activate PMNs. 
Pathogens in microbial dental plaque are capable of stimulating host cells to increase their 
matrix metalloproteinase (MMP) release which is considered among the indirect 
mechanisms of tissue destruction seen during periodontitis (Sorsa et al. 2006). Periodontal 
tissues are infiltrated mainly by neutrophilic granulocytes and PMN which play an 
important role in the development of inflammatory injury. Tobacco-induced degranulation 
events in neutrophils, tobacco-induced alterations to the microbial flora, and tobacco-
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induced increases in pro-inflammatory cytokine burden could each, theoretically, influence 
MMP-8 levels in the periodontal tissues of smokers. In a recent study (Özçaka et al. 2011), it 
was hypothesised that smoking may affect MMPs and neutrophil degranulation products in 
the systemic level eventually leading more severe periodontal tissue destruction and 
systemic inflammation predisposing to cardiovascular diseases (Pussinen et al. 2007). In that 
exploratory study, the serum concentrations of MMP-8, MMP-9, TIMP-1, NE, and MPO 
were evaluated comparatively in smoker versus non-smoker patients with chronic 
periodontitis as well as periodontally healthy subjects. The clinical periodontal 
measurements were recorded and serum samples were analyzed in 55 patients with the 
clinical diagnosis of chronic periodontitis (16 smoker and 39 non-smoker) and 56 
periodontally healthy subjects (17 smoker and 39 non-smoker). The findings of significantly 
elevated serum MMP-9, MPO, NE together with decreased TIMP-1 in smoker patients with 
chronic periodontitis than non-smoker counterparts support the idea that smoking together 
with periodontal destruction may expose/predispose to cardiovascular diseases. 
MMP-8 activity has been found to be modified in various organs and body fluids in tobacco 
smokers. Knuutinen et al. (2002) noted an increased MMP-8 concentration in the resulting 
fluid infiltrate in smokers compared to that in the non-smokers following the induction of 
suction blisters on the upper arm. Furthermore, Betsuyaku et al. (1999) have shown 
increased MMP-8 and MMP-9 activity in the bronchial alveolar lavage fluids of smokers 
with emphysema compared to those without emphysema. A significant correlation between 
increased MMP-8 levels and periodontal disease severity has been suggested. Liu et al. 
(2006) have reported increased local MMP-8 expression in the periodontal tissues of 
smokers compared to the non-smokers and a slight increase in the serum MMP-8 
concentration, although the difference between the smoker and non-smoker groups did not 
reach the level of significance.  
On the other hand, Söder et al. (2002) found a positive correlation between elastase 
complexed to α1-antitrypsin and MMP-8 concentrations in the gingival crevicular fluid 
(GCF) of smokers in individuals with various persistent periodontal diseases. However, 
they did not observe any difference in GCF MMP-8 levels between smokers and non-
smokers. Persson et al. (2003) reported that GCF MMP-8 levels remained unchanged in the 
smokers following surgical treatment for periodontitis, whereas decreased levels were 
observed in the non-smokers, suggesting a tobacco-induced MMP-8 burden. Liede et al. 
(1999) examined salivary MMP-8 concentrations in 327 smokers and 82 quitters and found 
lower MMP-8 levels in the current smokers than the ex-smokers. According to our recent 
data (Özçaka et al. 2011), serum MMP-8 concentrations did not differ significantly between 
the smokers and non-smokers. It should be kept in mind that self-reports of non-smoking 
people can sometimes be unreliable (Buduneli et al. 2006). Therefore, confirmation of the 
smoking status by serum and/or salivary cotinine analysis may result in changing the 
accurate group of individual subjects which may eventually affect the results. Therefore, 
apart from the relatively small numbers of smokers in some of the studies, lack of cotinine 
analysis may explain the discrepancies between the findings of different clinical studies. 
MPO was suggested as an early marker of systemic inflammation in smokers without severe 
airway symptoms in a study aiming to relate smoking and chronic obstructive pulmonary 
disease (Andelid et al. 2007). The authors reported significant increases in serum MPO 
concentrations in smokers than never smokers at 6th year of follow-up. Enhanced serum 
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levels of MPO indicate increased degranulation of specific granules of neutrophils (Rautelin 
et al. 2009). Accordingly, our recent data indicated significant increases in serum 
concentrations of MPO in smoker chronic periodontitis patients, although the clinical 
periodontal measurements did not differ from those of the non-smoker counterparts 
(Özçaka et al. 2011a). This increase in serum MPO concentration may be regarded as an 
indicator of increased risk for local and systemic inflammation such as periodontal tissue 
destruction or an early sign of atherosclerosis. 
NE, which is a serine protease, can also accelerate MMP-cascades by activating latent 
proMMPs and inactivating TIMP-1 (Sorsa et al. 2006). NE was suggested to be involved in 
the degradation of non-collagenous protein-covered collagen fibrils in the early destructive 
stages of periodontal diseases (Ujiie et al. 2007). To our best of knowledge, serum NE levels 
as a systemic inflammatory parameter reflecting effects of smoking on chronic periodontitis 
has been evaluated only in our recent study (Özçaka et al. 2011) which revealed significantly 
higher serum NE concentrations in smoker chronic periodontitis patients than those of non-
smokers. 
Significantly increased serum concentrations of MMP-9 together with significant decreases 
in TIMP-1 concentrations in smoker chronic periodontitis patients deserve further 
investigation and suggest that chronic periodontitis together with smoking can predispose 
the development of cardiovascular diseases (Pussinen et al. 2007). Persistent smoking and 
periodontal inflammation predispose the patients for enhanced systemic inflammation in 
addition to enhanced periodontal destruction. 
Carboxyterminal-telopeptide pyridinoline cross-links of type I collagen (ICTP) is released 
into the periodontal tissues as a consequence of collagen degradation and alveolar bone 
resorption (Seibel 2003). Type I collagen composes 90 % of the organic matrix of bone and is 
the most abundant collagen in osseous tissue (Narayanan & Page 1983). Studies assessing 
the role of ICTP levels in GCF or peri-implant crevicular fluid as a diagnostic marker of 
periodontal disease activity have reported promising results so far (Oringer et al. 1998, 
2002). ICTP was suggested to predict future bone loss, to correlate with clinical parameters 
and putative periodontal pathogens and also to reduce following periodontal therapy 
(Giannobile 1999). Apart from the direct cigarette smoke-mediated effects, tissue damage 
mediated by impaired balance of bone turnover markers originating from tobacco smoke 
and tobacco-induced inflammation may be a potential mechanism. 
Osteocalcin (OC) is a calcium-binding protein of bone and the most abundant non-
collagenous protein of the mineralized tissue (Lian & Gundberg 1988). Serum level of OC is 
considered as a marker of bone formation (Christenson 1997). Serum levels of OC were 
reported to be lower in periodontitis patients compared with healthy subjects suggesting 
lower osteoblastic activity and bone formation ability (Shi et al. 1996). 
In a recent study, we investigated possible effects of smoking on saliva ICTP and OC 
concentrations comparatively in patients with chronic periodontitis and periodontally 
healthy subjects (Özçaka et al. 2011b). Smoker periodontitis patients revealed similar clinical 
periodontal index values with non-smoker counterparts, whereas salivary OC levels were 
lower in smokers than non-smokers. ICTP levels in non-smoker chronic periodontitis 
patients were higher than non-smoker controls and smoker healthy control group revealed 
higher ICTP levels than non-smoker counterparts. The data suggested that suppression of 
www.intechopen.com
 
Pathogenesis and Treatment of Periodontitis 
 
86
salivary OC level by smoking may at least partly explain the deleterious effects of smoking 
on periodontal status. In another recent study by our group (Gürlek et al. 2009) similar 
salivary ICTP levels were detected in smoker, non-smoker and ex-smoker patient groups 
with similar clinical periodontal findings. Smoking status was confirmed by salivary 
cotinine analysis but there was no clinically healthy control group in that study and the 
number of teeth present, average probing depths and attachment levels were all similar in 
the three study groups. There were no significant differences in saliva ICTP concentrations 
between the smoker and non-smoker patient groups. It may be suggested that the similarity 
in clinical periodontal disease parameters may explain the similar salivary ICTP levels 
obtained in these studies.  
Significantly lower salivary OC concentrations in both healthy and diseased smokers than 
their non-smoker counterparts were reported by Özçaka et al. (2011b). The detrimental 
effects of smoking may explain these decreases in salivary levels of OC in smokers also 
indicating a deficiency in tissue response to the injuries in smoker subjects. The differences 
in patient numbers and/or the possible differences in the disease activity states may explain 
the differences in findings of the present study and the previous ones. On the other hand, 
significantly lower salivary OC concentrations in the smoker patients than the non-smokers 
as well as the ex-smokers may at least partly explain the mechanisms of negative effects of 
smoking on periodontal health. 
Lymphocyte functions including antibody production may also be affected by smoking. 
However, such affects seem to be complex and some components of cigarette such as 
nicotine are immunosuppressive (Geng et al. 1996) whereas some others are 
immunostimulatory such as tobacco glycoprotein and metals (Francus et al. 1988, Brooks et 
al. 1990). Serum immunoglobulin G (IgG) levels were reduced in smoker patients with 
periodontitis (Quinn et al. 1998). On the other hand, the number of B lymphocytes seemed 
to be similar in smokers and non-smokers but their function in peripheral blood was 
impaired in smokers, as reflected in proliferative response to polyclonal B cell activators and 
antigens (Sopori et al. 1989). 
Interleukin-1 (IL-1), tumour necrosis factor (TNF), and prostaglandin E2 (PGE2) are among 
the major inflammatory mediators that play significant role in alveolar bone resorption. 
Increased GCF levels of TNF-alpha were detected in current and former smokers (Bostrom 
et al. 1998). Moreover, it was reported that the expressions of inflammatory mediators such 
as IL-1, IL-6, IL-8, TNF-α, and cyclooxygenase-2 (COX-2) in response to lipopolysaccharide 
(LPS) of gram negative bacteria were increased in smokers (Bostrom et al. 1999, Tappia et al. 
1995, Kuschner et al. 1996). 
Tobacco smoking mostly in the form of cigarette smoking has been accused of impairing 
microcirculatory system and the relevant changes in vascular formations and functions 
may have a negative influence on the immune and inflammatory reactions in periodontal 
tissues. Smokers were reported to have significantly less number of vessels in inflamed 
gingival tissue compared to non-smokers (Rezavandi et al. 2002). Long-term smoking has 
an established negative effect on the vasculature of periodontal tissues. Acute exposure to 
cigarette smoke induces gingival hyperaemia, which is caused by the concomitant 
increase in blood pressure against a small but significant sympathetically induced 
vasoconstriction in healthy gingiva (Mavropoulos et al. 2003). Smoking even one cigarette 
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has been suggested to have the potential to cause a decrease in gingival blood flow 
(Mavropoulos et al. 2007). Such small but repeated vasoconstrictive attacks and 
impairment of revascularization due to cigarette smoking may contribute to disruption of 
immune response and delay in the healing response, leading to an increased risk of 
periodontal disease (Ojima & Hanioka 2010). Vascular dysfunction may also reduce 
oxygen delivery to gingival tissue. Pocket oxygen tension was reported to be significantly 
lower in smokers than non-smokers providing support for the negative effects of smoking 
on vascular system (Hanioka et al. 2000). Evidence from both human and experimental 
studies suggests that smoking has a long-term chronic effect, and its effect is not simply a 
vasoconstriction. Its suppressive effects on the vascular system of gingiva can be observed 
through less gingival redness, lower bleeding on probing and fewer vessels visible 
clinically and histologically.  
A better understanding of the influence of tobacco smoke on the host response to 
periodontal infection has been the major concern in numerous studies whereas, limited 
research has been published aiming to identify the influence of tobacco smoke on the dental 
biofilm. Tobacco smoke has been shown to cause shifts in the microbial species that 
comprise dental plaque (Haffajee & Socransky 2001, Kamma et al. 1999, Shiloah et al. 2000, 
Umeda et al. 1998, van Winkelhoff et al. 2001, Zambon et al. 1996). In a recent study by our 
group (Buduneli et al. 2011), it was hypothesized that tobacco may induce alterations to the 
molecular structure of lipid A in a manner consistent with reduced inflammatory potential. 
Therefore, the ratios of 3-OH fatty acids in smoking and non-smoking chronic periodontitis 
patients were investigated. The findings suggested that smoking induces specific structural 
alterations to the lipid A-derived 3-OH fatty acid profile in saliva that are consistent with an 
oral microflora of reduced inflammatory potential. Such data may explain increased 
infection with periodontal pathogens but reduced clinical inflammation in smokers. 
However, further studies are warranted to better clarify this issue. 
In a systematic review, Bergstrom (2006) concluded that 100% of 70 cross-sectional studies 
and 100% of 14 case-control studies indicate an association between smoking and an 
impaired periodontal health condition, and 95% of 21 cohort studies indicate a greater 
periodontal health impairment rate in smokers than in non-smokers. Therefore, he 
suggested that there is good evidence to recommend smoking to be specifically considered 
in a periodontal health examination. Indeed, in a review by Hilgers & Kinane (2004) it was 
concluded that smoking cessation is indicated in the promotion of better general health and 
in the improvement of periodontal health. Considering the existing evidences, the authors 
suggested that dentists should offer to refer patients for smoking cessation counselling. 
In conclusion, smoking is accepted as a strong risk factor for destructive periodontal disease. 
Gelskey (1999) stated that smoking meets most of the criteria for causation proposed by Hill 
(1965). This statement is based on the consistency and strength of association between 
smoking and periodontal disease severity demonstrated by multiple cross-sectional as well 
as longitudinal studies. Further evidence comes from the dose effect of smoking on 
periodontal disease severity and a slowing of disease progression in patients who quit 
smoking. Furthermore, smoking has a negative impact on periodontal treatment outcomes. 
Smoking is harmful virtually to every tissue in the body. The basis for these deleterious 
effects is related to the adverse impact of smoking on microbial and host factors. 
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The proposed mechanisms for the negative effects of smoking on periodontal health were 
summarised by Johnson & Guthmiller (2007) as follows; decreased immunoglobulin G2 
production, chronic reduction in blood flow and vascularity, increased prevalence of 
potential periodontal pathogens, shift in neutrophil function towards destructive activities, 
negative effects on cytokine and growth factor production and inhibition of fibroblast 
growth, attachment and collagen production.  
In addition to be accepted as an important risk factor for destructive periodontal disease, 
smoking has been suggested to interfere with the outcomes of various periodontal therapies. 
Bostrom (2006) systematically reviewed the intervention studies both in terms of non-
surgical and surgical periodontal therapy. It was concluded that the results of the 
intervention studies suggest an inferior therapeutic outcome in smoker patients compared 
to non-smoker counterparts. The author reports that in 80% of studies the results were 
statistically significant. When measured in terms of mean probing depth reduction or mean 
clinical attachment level gain after a maximum of 9 months, the outcome on the average is 
less efficient in smokers than in non-smokers (Bostrom 2006). However, none of the non-
surgical intervention studies has evaluated the effect of smoking in terms of a successful 
versus a non-successful outcome following predetermined criteria. Furthermore, it was 
stated that it is still not known whether or not a negative short-term effect of smoking 
observed in terms of probing depth or clinical attachment level holds true in the long run as 
tooth loss. Most of the intervention studies have a rather short follow-up period and 
therefore unable to provide an answer in terms of the rate of tooth loss. It is quite clear that 
further intervention studies with larger scales and longer follow-ups are required to better 
clarify this issue. Smoking more than 10 cigarettes per day is considered as heavy smoking 
and heavy smokers have a poorer treatment response than non-smokers or ex-smokers 
(Kaldahl et al. 1996, Norderyd 1998).  
A meta-analysis by Labriola et al. (2005) evaluated the impact of smoking on non-surgical 
periodontal therapy and reported that probing depth reduction in sites where probing 
depth was initially equal to or more than 5 mm was significantly greater in non-smokers 
than in smokers in eight studies (Grossi et al. 1997, Mongardini et al. 1999, Palmer et al. 
1999, Preber et al. 1995, Pucher et al. 1997, Renvert et al. 1998, Ryder et al. 1999, Williams et 
al. 2001).  
In a recent intervention study (Buduneli et al. 2009),  effects of initial periodontal treatment 
on GCF levels of interleukin-17 (IL-17), sRANKL, and OPG in smoker versus non-smoker 
patients with chronic periodontitis. All clinical periodontal measurements decreased 
significantly after the initial periodontal treatment in both the smoker and non-smoker 
patient groups. There were no significant differences between the smoker and non-smoker 
patients in regards with the changes in clinical periodontal data following initial periodontal 
treatment. Data indicated that GCF volume, OPG total amount and concentration decreased 
in both smokers and non-smokers after scaling and root planning (SRP), whereas IL-17 
concentration increased. sRANKL levels did not differ between groups or with SRP. 
Significant correlations were found between baseline IL-17 and RANKL levels, baseline 
papilla bleeding on probing and OPG levels. According to the findings, it was suggested 
that neither smoking nor periodontal inflammation appears to influence GCF RANKL levels 
in systemically healthy patients with chronic periodontitis. Smoker and non-smoker patients 
with chronic periodontitis seem to be affected indifferently by the initial periodontal 
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treatment in regards with GCF IL-17 and OPG concentrations. Smoking seems to suppress 
OPG synthesis and might be contributory to increased bone destruction often seen in 
smokers. 
Surgical periodontal therapy aims to eliminate periodontal pockets and obtain 
physiological contours in both soft and hard periodontal tissues. As with the non-surgical 
intervention studies, the primary outcome measures in surgical intervention studies are 
probing depth and clinical attachment level. On the basis of a systematic review, Bostrom 
(2006) reported that 91% of 10 non-surgical and 93% of 14 surgical therapy intervention 
studies indicate an untoward effect of smoking on the therapeutic outcome. The author 
concluded that there is limited but consistent evidence to suggest that smoking negatively 
interferes with the therapy outcomes of nonsurgical as well as surgical periodontal 
interventions. 
Haesman et al. (2006) also reviewed the clinical evidence for the relative clinical responses to 
periodontal treatment in smokers, non-smokers and ex-smokers. The authors concluded that 
data from epidemiological, cross-sectional and case-control studies strongly suggest that 
quitting smoking is beneficial to patients following periodontal treatments. The response of 
ex-smokers to periodontal treatment suggests that quitting smoking helps to improve the 
clinical periodontal status but there are only limited data from long-term longitudinal 
clinical trials to demonstrate unequivocally the periodontal benefit of quitting smoking. It is 
clear that long-term, longitudinal clinical trial that monitors over several years the response 
to treatment in a cohort of smokers with chronic periodontitis will provide valuable data on 
the detrimental effects of smoking. However, such a study is definitely not easy to conduct 
both from the practical and financial points of view. At present, the dental profession can 
rely on the strong evidence base of the epidemiological, cross-sectional, and case-control 
studies concluding that quitting smoking is likely to be beneficial to oral and in particular 
periodontal health.  
Johnson & Guthmiller (2007) suggested that smoking cessation cannot reverse the negative 
past effects of smoking; however, the rate of bone and attachment loss slows after patients 
quit smoking. Periodontal disease severity in former smokers falls between that of current 
smokers and never smokers (Bergstrom et al. 2000, Jansson & Lavstedt 2002, Tomar & Asma 
2000, Torrunggruang et al. 2005). Preshaw et al. (2005) evaluated the effect of smoking 
cessation on non-surgical periodontal treatment in 49 smokers who wanted to quit smoking. 
Therapy included individualised cessation interventions, scaling and root planning and oral 
hygiene instructions followed by maintenance phase of periodontal treatment. Only 26 
patients completed the study; 10 successfully stopped smoking, 10 continued smoking, and 
six stopped but relapsed during the study period. The authors reported that the patients 
who successfully quit smoking had the best response to therapy; the “oscillators” had an 
intermediate response to the non-smokers and quitters. These results underscore the 
challenges of cessation of tobacco smoking. Counselling on the benefits of smoking cessation 
by dentists may encourage the patients to seek periodontal therapy and eventually lead to 
improved periodontal health. Likewise, Borrell & Papapanou (2005) suggested that smoking 
cessation is a key in the prevention and control of periodontal disease because it affects both 
the bacterial and host etiological components in the disease process.  
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In conclusion, the data from both cross-sectional and epidemiological studies over the past 15 
years evaluating the relationship between smoking and periodontal diseases suggest that there 
is strong evidence of a positive association between smoking and clinical and biochemical 
signs of periodontitis, as well as an increased risk of periodontitis in smokers. Furthermore, the 
evidence for smoking having a deleterious effect on periodontal treatment outcomes is quite 
convincing but still needs more data from longitudinal intervention studies. 
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